Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study

Table 2

ΔHbA_1c at weeks 12 and 24 for patients of the 3 TG-based tertiles in the VLDM and HDM groups (FAS LOCF).

ΔHbA1c	VLDM				HDM
	1^st tertile	2^nd tertile	3^rd tertile		1^st tertile	2^nd tertile	3^rd tertile
Week 12
Sample size ()	799	837	798	—	168	154	150	—
Mean ± SD (%)	-	-	-	—	-	-	-	—
Univariate analysis
LSMean (SE) (%)	-	-	-^ς	0.007	-	-	-	0.332
Multivariate analysis
LSMean (SE) (%)	-	-	-^ς	0.008	-	-	-9	0.503
Week 24
Sample size ()	808	847	804	—	169	154	148	—
Mean ± SD (%)	-	-	-	—	-	-	-	—
Univariate analysis
LSMean (SE) (%)	-	-	-^ς	0.025	-	-	-	0.064
Multivariate analysis
LSMean (SE) (%)	-	-	-	0.113	-	-	-	0.184

3^rd tertile vs. 1^st tertile: ; ^ς3^rd tertile vs. 2^nd tertile: . 1^st tertile: ; 2^nd tertile: ; 3^rd tertile: ; ΔHbA_1c: glycated hemoglobin (HbA_1c) change from baseline; VLDM: vildagliptin (50 mg bid) plus metformin (500 mg bid); HDM: metformin uptitration (1000 mg bid); FAS: full analysis set; LOCF: last observation carried forward; LSMean: least square mean. The univariate analysis used the TG subgroups as the variable and baseline HbA_1c as the covariate.